Phase II Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer - Related Studies

Phase II Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer (GAO1)

This study is currently recruiting participants.

Study NCT00619996. Last updated on May 27, 2008. Information provided by Italian Trial in Medical Oncology

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Prostate Cancer

2	Additional conditions recognized in this trial
		Prostatic Neoplasms

3	More general conditions related to this trial
		Genital Diseases, Male
		Genital Neoplasms, Male
		Neoplasms
		Neoplasms by Site
		Prostatic Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		Sorafenib (Nexavar) and Docetaxel

5	Additional drug interventions recognized in this trial
		Docetaxel
		Sorafenib

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protein Kinase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Italian Trial in Medical Oncology